Oramed Pharmaceuticals (ORMP) 10-K 25 Nov 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2015	Nov. 24, 2015	Feb. 28, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	1,176,309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-K
Document Period End Date	Aug. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 44,469,184
Entity Common Stock, Shares Outstanding		11,599,825

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 3,213	$ 1,762
Short term deposits (note 2)	11,928	18,481
Marketable securities (note 3)	2,088	1,047
Restricted cash	16	16
Prepaid expenses and other current assets	$ 127	64
Related parties (note 13c)		330
Grants receivable from the chief scientist		78
Total current assets	$ 17,372	21,778
LONG TERM ASSETS:
Long term deposits and investment (note 4)	8,022	$ 3
Marketable securities (note 3c)	940
Amounts funded in respect of employee rights upon retirement (note 7)	9	$ 7
Property and equipment, net (note 5)	11	14
Total long term assets	8,982	24
Total assets	26,354	21,802
CURRENT LIABILITIES -
Accounts payable and accrued expenses	953	$ 926
Advance on account of license agreement (note 1a1)	500
Related parties (note 13c)	36	$ 47
Total current liabilities	1,489	973
LONG TERM LIABILITIES:
Employee rights upon retirement (note 7)	11	9
Provision for uncertain tax position (note 12e)	26	27
Total long term liabilities	$ 37	$ 36
COMMITMENTS (note 8)
STOCKHOLDERS' EQUITY:
Common stock, $ 0.012 par value (30,000,000 authorized shares as of August 31, 2015 and 2014; 11,563,077 and 10,102,555 shares issued and outstanding as of August 31, 2015 and 2014, respectively)	$ 138	$ 121
Accumulated other comprehensive income	558	452
Additional paid-in capital	59,184	48,040
Accumulated loss	(35,052)	(27,820)
Total stockholders' equity	24,828	20,793
Total liabilities and stockholders' equity	$ 26,354	$ 21,802

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2015	Aug. 31, 2014
Balance Sheets [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	11,563,077	10,102,555
Common stock, shares outstanding	11,563,077	10,102,555

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Income Statement [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET	$ 4,781	$ 3,277	$ 2,272
GENERAL AND ADMINISTRATIVE EXPENSES	2,602	2,629	2,032
OPERATING LOSS	7,383	5,906	4,304
FINANCIAL INCOME (note 11a)	(168)	(225)	(180)
FINANCIAL EXPENSES (note 11b)	18	11	313
LOSS BEFORE TAXES ON INCOME	7,233	5,692	4,437
INCOME TAX EXPENSES (BENEFIT) (note 12c)	(1)	4	(205)
NET LOSS FOR THE YEAR	7,232	5,696	4,232
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	$ (3)	(34)	(131)
RECLASSIFICATION ADJUSTMENT FOR GAINS INCLUDED IN NET LOSS		80	90
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	$ (103)	(194)	(263)
TOTAL OTHER COMPREHENSIVE INCOME	(106)	(148)	(304)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 7,126	$ 5,548	$ 3,928
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.67	$ 0.62	$ 0.59
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	10,820,465	9,244,059	7,209,283

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock		Additional paid-in capital	Accumulated other comprehensive income	Accumulated loss
BEGINNING BALANCE at Aug. 31, 2012	$ 3,778	$ 80		$ 21,590		$ (17,892)
BEGINNING BALANCE, Shares at Aug. 31, 2012		6,675
SHARES AND WARRANTS ISSUED (see note 9b)	1,422	$ 4		1,418
SHARES AND WARRANTS ISSUED (see note 9b), Share		349
SHARES ISSUED	4,239	$ 8		4,231
SHARES ISSUED, Shares		658
SHARES ISSUED FOR MARKETABLE SECURITIES (see note 9c)	628	$ 2		626
SHARES ISSUED FOR MARKETABLE SECURITIES (see note 9c), Share		199
SHARES ISSUED FOR SERVICES	245	$ 1		244
SHARES ISSUED FOR SERVICES, Shares		34
EXCHANGE OF WARRANTS (see note 6)	918			918
EXERCISE OF WARRANTS AND OPTIONS	110		[1]	110
EXERCISE OF WARRANTS AND OPTIONS, Share		23
STOCK BASED COMPENSATION	719			$ 719
STOCK BASED COMPENSATION, Shares
TOTAL OTHER COMPREHENSIVE INCOME	(304)				$ 304
NET LOSS	4,232					$ (4,232)
ENDING BALANCE at Aug. 31, 2013	8,131	$ 95		$ 29,856	$ 304	$ (22,124)
ENDING BALANCE, Shares at Aug. 31, 2013		7,938
SHARES ISSUED FOR CASH, NET (see note 9e)	14,887	$ 19		14,868
SHARES ISSUED FOR CASH, NET (see note 9e), Shares		1,580
SHARES ISSUED	102		[1]	102
SHARES ISSUED, Shares		16
EXERCISE OF WARRANTS AND OPTIONS	1,753	$ 7		1,746
EXERCISE OF WARRANTS AND OPTIONS, Share		569
STOCK BASED COMPENSATION	1,468			$ 1,468
STOCK BASED COMPENSATION, Shares
TOTAL OTHER COMPREHENSIVE INCOME	(148)				$ 148
NET LOSS	5,696					$ (5,696)
ENDING BALANCE at Aug. 31, 2014	20,793	$ 121		$ 48,040	$ 452	(27,820)
ENDING BALANCE, Shares at Aug. 31, 2014		10,103
SHARES ISSUED	$ 93		[1]	93
SHARES ISSUED, Shares		15
SHARES ISSUED FOR MARKETABLE SECURITIES (see note 9c)
STOCK BASED COMPENSATION	$ 1,347		[1]	$ 1,347
STOCK BASED COMPENSATION, Shares		33
TOTAL OTHER COMPREHENSIVE INCOME	(106)				106
EXERCISE OF OPTIONS	8		[1]	$ 8
EXERCISE OF OPTIONS, Shares		1
SHARES, OPTIONS AND WARRANTS ISSUED FOR CASH, NET	9,713	$ 17		$ 9,696
SHARES, OPTIONS AND WARRANTS ISSUED FOR CASH, NET, Share		1,411
NET LOSS	7,232					(7,232)
ENDING BALANCE at Aug. 31, 2015	$ 24,828	$ 138		$ 59,184	$ 558	$ (35,052)
ENDING BALANCE, Shares at Aug. 31, 2015		11,563
[1]	Represents an amount of less than $1.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$ (7,232)	$ (5,696)	$ (4,232)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		4	6	5
Exchange differences and interest on investments		(20)	(29)	19
Stock based compensation		1,347	1,468	719
Common stock issued for services		$ 93	102	244
Gain on sale of investment			$ (80)	(50)
Exchange of warrants				297
Changes in fair value of warrant liabilities				(45)
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and related parties		$ 345	$ (319)	(3)
Accounts payable, accrued expenses and related parties		516	475	(146)
Liability for employee rights upon retirement		2	1	1
Provision for uncertain tax position		(1)	4	(205)
Total net cash used in operating activities		(4,946)	(4,068)	(3,396)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1)	(14)	(6)
Purchase of short term and long term deposits		(21,125)	$ (55,750)	$ (5,847)
Purchase of held to maturity securities		(1,885)
Proceeds from sale of short term deposits		$ 19,701	$ 42,539	$ 1,054
Proceeds from sale of available-for-sale securities			137	227
Funds in respect of employee rights upon retirement		$ (2)	(2)	(2)
Other			2	5
Total net cash used in investing activities		$ (3,312)	(13,088)	(4,569)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, options and warrants - net of issuance expenses*	[1]	9,713	14,887	5,715
Proceeds from exercise of warrants and options		8	1,753	109
Total net cash provided by financing activities		9,721	16,640	5,824
EFFECT OF EXCHANGE RATE CHANGES ON CASH		(12)	6	(18)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		1,451	(510)	(2,159)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		1,762	2,272	4,431
CASH AND CASH EQUIVALENTS AT END OF PERIOD		$ 3,213	$ 1,762	2,272
Material non cash investing and financing activities:
Exchange of warrants				918
Shares issued for marketable securities				$ 628
[1]	See notes 9b, 9d, 9e, 9f and 9h.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Aug. 31, 2015
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES: a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the “Subsidiary”). On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware. On July 3, 2015, the Company and the Subsidiary entered into a non-binding Letter of Intent (the “LoI”) with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd. (“HLST” and together - “Sinopharm-HLST”), according to which, the Company will enter into a Stock Purchase Agreement with Sinopharm-HLST pursuant to which Sinopharm-HLST will agree to buy and the Company will agree to sell an aggregate of 1,155,367 shares of its common stock, or the Shares, at a price per Share of approximately $10.39 (and $12,000 in total), and in addition, the Subsidiary will grant a commercialization license in the territory of Peoples Republic of China (the “Territory”) related to oral insulin, for an aggregate of approximately $38,000, of which $18,000 would be paid up front, and $20,000 would be payable upon achievement of a certain milestone, and royalties of 10% on net sales of the related commercialized products to be sold by Sinopharm-HLST in the Territory. In July 2015, according to the LoI, Sinopharm-HLST paid the Subsidiary a non-refundable amount of $500 2) Development and liquidity risks The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities. Based on its current cash resources and commitments, and cash received in private and public offerings in the years ended August 31, 2015 and 2014, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond after the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months. b. Accounting principles The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation. d. Functional currency The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate. e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation. f. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities. Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses. g. Research and development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately. Grants received from the Office of Chief Scientist (“OCS”) and from the Bio-Jerusalem fund (“Bio-Jerusalem”) are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 8(i) and 8(j). h. Cash equivalents The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. i. Loss per common share Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and restricted stock units excluded from the calculation of diluted net loss was 2,953,962 for the year ended August 31, 2015 (1,924,491 and 2,343,972 for the years ended August 31, 2014 and 2013, respectively). j. Stock based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The fair value of share based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The expected service period is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior. The forfeitures are estimated based on historical experience and anticipated future conditions. The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method. k. Fair value measurement: Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. As of August 31, 2015, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1). In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. As of August 31, 2015, the carrying amount of cash and cash equivalents, short term deposits, prepaid expenses and other current assets and accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments. As of August 31, 2015, the carrying amount of long term deposits approximates their fair values due to the stated interest rates which approximate market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value. l. Marketable securities 1) Available-for-sale securities Available-for-sale equity securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses. 2) Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, management assesses whether there are any indicators that the value of the Company’s marketable securities may be impaired, which includes reviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and duration of the decline. In the Company’s evaluation, the Company considers its ability and intent to hold these investments for a reasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair value of the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To the extent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimated fair value in the security. m. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long term deposits and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote. n. Property and equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets. Annual rates of depreciation are as follows: % Computers and peripheral equipment 33 Office furniture and equipment 15-33 Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Short Term Deposits

Short Term Deposits	12 Months Ended
	Aug. 31, 2015
Short Term Deposits/ Long Term Deposits [Abstract]
SHORT TERM DEPOSITS:	NOTE 2 - SHORT TERM DEPOSITS: Composition August 31 2015 2014 Annual interest rate Amount Annual interest rate Amount Dollar deposits 0.3-1.52 % $ 11,928 0.12-0.6 % $ 18,481 During the year ended August 31, 2015, the Group purchased short term deposits of $13,123 and received proceeds from the sale of short term deposits of $19,701. During the year ended August 31, 2014, the Group purchased short term deposits of $55,750 and received proceeds from the sale of short term deposits of $42,539.

Marketable Securities

Marketable Securities	12 Months Ended
	Aug. 31, 2015
Marketable Securities [Abstract]
MARKETABLE SECURITIES:	NOTE 3 - MARKETABLE SECURITIES: a. Composition: The Group's marketable securities include investments in equity securities of D.N.A Biomedical Solutions Ltd (“D.N.A”) and in held to maturity bonds. Composition: August 31 2015 2014 Short term: D.N.A (see b below) $ 1,153 $ 1,047 Held to maturity bonds (see c below) 935 - $ 2,088 $ 1,047 Long term: Held to maturity bonds (see c below) $ 940 $ - b. D.N.A The investment in D.N.A. is reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities. The D.N.A. ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date. During the years ended August 31, 2014 and 2013, the Subsidiary sold in aggregate 2,625,989 and 5,250,000 of the D.N.A ordinary shares for a total of $138 and $170, respectively. In March 2013 the Company sold 1,750,000 of the D.N.A ordinary shares for $56. During the year ended August 31, 2015, the Group did not sell any of the D.N.A ordinary shares. As of August 31, 2015, the Group owns approximately 9.6% of D.N.A’s outstanding ordinary shares. The cost of the securities as of August 31, 2015 and 2014 is $590. The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into financial income (amounting to $80 and $90 during the years ended August 31, 2014 and 2013, respectively), were determined by specific identification. As of August 31, 2015 and 2014, the available for sale equity securities are classified as Level 1. c. Held to maturity bonds The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2015, are as follows: August 31, 2015 Amortized cost Gross unrealized losses Estimated fair value Short term: Commercial bonds $ 914 $ 1 $ 913 Accrued interest 21 - 21 Long term 940 3 937 $ 1,875 $ 4 $ 1,871 the yield to maturity rates vary between 0.57% to 1.31%.

Long Term Deposits

Long Term Deposits	12 Months Ended
	Aug. 31, 2015
Short Term Deposits/ Long Term Deposits [Abstract]
LONG TERM DEPOSITS	NOTE 4 - LONG TERM DEPOSITS: Composition: August 31 2015 2014 Bank deposits (1) $ 8,017 $ - Lease car deposits 4 2 Investment 1 1 $ 8,022 $ 3 (1) Represents U.S. dollar bank deposits which carry fixed annual interest rates between 1.28% to 1.64%, with maturities of more than one year from August 31, 2015. The latest maturity date is during the year ending August 31, 2017.

Property and Equipment Net

Property and Equipment Net	12 Months Ended
	Aug. 31, 2015
Property and Equipment Net [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5 - PROPERTY AND EQUIPMENT, NET: a. Composition of property and equipment, grouped by major classifications, is as follows: August 31 2015 2014 Cost: Leasehold improvements $ 78 $ 78 Office furniture and equipment 29 28 Computers and peripheral equipment 38 38 145 144 Less - accumulated depreciation and amortization 134 130 $ 11 $ 14 b. Depreciation expenses totaled $4, $6 and $5 in the years ended August 31, 2015, 2014 and 2013.

Warrants

Warrants	12 Months Ended
	Aug. 31, 2015
Warrants [Abstract]
Warrants	NOTE 6 - WARRANTS As part of the Company’s private placements in 2011 and 2012, three warrants to purchase in aggregate 311,797 shares were granted to a Leading Investor, as defined in note 9a (collectively, the “Warrants”). The Warrants were granted for five years at an initial exercise price of $6.00 per share. The Warrants included a full ratchet anti-dilution protection from the second year anniversary date after issuing the warrant, subject to certain limitations. In the event the Company was to issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or was to issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants were to be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants were to be updated. As a result of a private placement in August 2012, and the agreement with D.N.A from October 2012, as described in note 9c, the warrant that was issued in 2011 was twice amended in such that its exercise price was reduced to $3.7656 per share and the number of shares issuable upon its exercise was increased to 290,459. On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the “Agreement”) in connection with the Warrants, pursuant to the which, the Company and the Leading Investor agreed to amend the Warrants to remove the anti-dilution protection in its entirety. In addition, as to the Warrants issued in August and November 2012, the exercise price was reduced to $3.7656 per share. On that day, the Company also issued to the Leading Investor an additional warrant to purchase up to 137,311 shares of the Company over a period of four years at an exercise price of $7.20 per share. The fair value of the new warrant at the date of grant was $145, using the following assumptions: dividend yield of 0%, expected term of four years, expected volatility of 62.29% and risk-free interest rate of 0.57%. The fair value of the warrants was determined by using a Monte Carlo type model based on the risk neutral approach. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result in a higher fair value measurement. In addition to the new warrants, the Company’s President, Chief Executive Officer and director (the “CEO”), in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Warrants, as amended, would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from the CEO such number of shares of common stock of the Company owned by the CEO equal to such excess, up to a maximum of 112,690 shares of common stock of the Company (the “CEO Option”). The foregoing right shall survive until the expiration date of such Warrants. The fair value of the CEO Option on the date of grant was $168, based on the Monte Carlo type model and was recognized as an expense against the stockholders equity. Following the removal of the anti-dilution protection, the Warrants were no longer classified as liabilities. The Company recognized a financial expense in the amount of $297 during the three months ended November 30, 2012. The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs for the year ended August 31, 2013. There were no Level 3 items for the years ended August 31, 2015 and 2014. Year ended August 31, 2013 Carrying value at the beginning of the period $ 637 Additions 28 Changes in fair value (44 ) Exchange of warrants (621 ) Carrying value at the end of the period $ - See note 9i with respect to outstanding warrants.

Employees Rights Upon Retiremen

Employees Rights Upon Retirement	12 Months Ended
	Aug. 31, 2015
Employee Rights Upon Retirement [Abstract]
EMPLOYEES RIGHTS UPON RETIREMENT	NOTE 7 - EMPLOYEES RIGHTS UPON RETIREMENT: The Subsidiary is required to make a severance payment upon dismissal of an employee, or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month’s salary for each year employed) is recorded on the Subsidiary’s balance sheets under “Liability for employee rights upon retirement.” The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis. The liability is funded in part by the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Subsidiary’s balance sheets under “Funds in respect of employee rights upon retirement.” These policies are the Subsidiary’s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In each of the years ended August 31, 2015, 2014 and 2013, the Subsidiary deposited $2 with insurance companies in connection with its severance payment obligations. In accordance with the current employment agreements with certain employees, the Subsidiary makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee’s rights upon retirement. The Subsidiary is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Subsidiary’s balance sheets, as the amounts funded are not under the control and management of the Subsidiary and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the “Contribution Plans”). The amounts of severance pay expenses were $26, $26 and $23 for the years ended August 31, 2015, 2014 and 2013, respectively. In the years ended August 31, 2015, 2014 and 2013, the Group paid $24, $26 and $13, respectively, in respect of a Contribution Plan. The Subsidiary expects to contribute approximately $26 in the year ending August 31, 2016 to insurance companies in connection with its severance liabilities for its operations for that year.

Commitments

Commitments	12 Months Ended
	Aug. 31, 2015
Commitments [Abstract]
COMMITMENTS	NOTE 8 - COMMITMENTS: a. In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd (“Entera”) to D.N.A (see also note 3), retaining a 3% interest, which is accounted for as a cost method investment (amounting $1). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450, with an annual interest rate of 0.45% that was fully paid in November 2011, and 8,404,667 ordinary shares of D.N.A. As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2015, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary. b. On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, the Company's Medical and Chief Technology Officer (the “CTO”) and Dr. Daniel Schurr (the “Hadasit Agreement”) to retain consulting and clinical trial services. According to the Hadasit Agreement, Hadasit will be entitled to consideration of $200 to be paid by the Company in accordance with the actual progress of the studies, $111 of which were recognized through August 31, 2015. See also note 1a(1). c. On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the “Consultant”) for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on March 31, 2011 and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The fair value of the option as of August 31, 2015 was $113, using the following assumptions: dividend yield of 0%; expected term of 5.46 years; expected volatility of 81.06%; and risk-free interest rate of 1.94%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method. d. On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel. The new lease agreement is for a period of 36 months commencing November 4, 2013. The annual lease payment will be NIS 89 from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of August 31, 2015, the future annual lease payments under the new agreement will be $23, based on the exchange rate as of August 31, 2015). The lease expenses for the years ended August 31, 2015, 2014 and 2013 were $23, $27 and $13, respectively. The future lease payments under the lease agreement are $23 and $2, respectively, in the years ending August 31, 2016 and 2017. As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments. e. The Subsidiary has entered into operating lease agreements for vehicles used by its employees for a period of 3 years. The lease expenses for the years ended August 31, 2015, 2014 and 2013 were $16, $28 and $30, respectively. The future lease payments under the lease agreement are $15 and $9 for the years ending August 31, 2016 and 2017, respectively. As security for its obligation under the lease agreements the Subsidiary deposited $4, which are classified as long term deposits. f. On April 15, 2013, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and 15,000 shares of the Company’s common stock. On July 11 and November 4, 2013, the Company issued to such advisor 5,000 and 10,000 shares, respectively. The fair value of the shares at these dates was $35 and $64, respectively. On May 13, 2014, the Company entered into an additional consulting agreement with the same third party advisor for a period of an additional twelve months, pursuant to which such advisor provided investor relations services and was entitled to receive a monthly cash fee and 15,000 shares of the Company’s common stock that were issued in four equal installments, on On July 1, 2015, the Company entered into an additional consulting agreement with the same third party advisor for a period of an additional twelve months, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 15,000 shares of the Company’s common stock that will be issued in four equal installments, on g. On February 6, 2014, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a Clinical Research Organization (“CRO”), for its clinical trial for an oral insulin capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary paid the CRO a total amount of approximately On July 22, 2014, the Subsidiary entered into an additional agreement with the same CRO, for its Phase 2b clinical trial for an oral insulin capsule for type 2 diabetes patients, which began in the second quarter of calendar year 2015. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $3,290 during the term of the engagement and based on achievement of certain milestones, $1,318 of which were recognized through August 31, 2015. h. On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102, all of which was recognized through August 31, 2014. On March 3, 2014, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $311, $40 of which was recognized through August 31, 2015, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement, none of which was recognized through August 31, 2015. On May 15, 2014, the Subsidiary entered into an additional agreement with the same vendor for the process development and production of the same capsule ingredients in the amount of $217, all of which was recognized through August 31, 2015. On December 12, 2014, the Subsidiary entered into an additional agreement with the same vendor, for the process development and production of the same capsule ingredients in the amount of $550, $430 of which was recognized through August 31, 2015. i. Grants from Bio-Jerusalem The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65. As of August 31, 2015, the Subsidiary had not yet realized any revenues and did not incur any royalty liability. During the years ended August 31, 2015 and 2014, the Company received no grants from Bio-Jerusalem. For the year ended August 31, 2013, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $12. j. Grants from the OCS Under the terms of the Company’s funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR. At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties. On August 31, 2015, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through August 31, 2015 was $2,194. k. For the years ended August 31, 2015, 2014 and 2013, the research and development expenses are presented net of OCS and Bio-Jerusalem fund grants, in the total amount of $49, $428 and $297, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Aug. 31, 2015
Stockholders' Equity [Abstract]
STOCK HOLDERS' EQUITY	NOTE 9 - STOCKHOLDERS’ EQUITY: The following are the significant capital stock transactions that took place during the years ended August 31, 2015, 2014 and 2013: a. In August 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 801,942 units at a purchase price of $4.44 per unit for total consideration of $3,560. Each unit consisted of one share of the Company and one common stock purchase warrant. Each warrant entitles the holder to purchase half a share exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, one of the investors who was previously defined as a leading investor (the "Leading Investor"), who purchased 225,226 of the units, was granted the right to maintain its percentage of the shares of the Company’s common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock. In addition, such investor’s warrants contained anti-dilution protection (the "full ratchet anti-dilution protection") and cashless exercise provisions not contained in the other investors’ warrants. The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to the 2011 Warrants, see note 6. In addition, in August 2012, the Company entered into a Securities Purchase Agreement with an investor for the sale of 5,652 units at same terms as describe above. As the payment from said investor was received during September 2012, following which, the Company issued him 5,652 shares of its common stock and a warrant to purchase 2,826 shares of its common stock, the proceeds from that investment, of $25 were presented as shares and warrants to be issued for cash. The Company paid cash consideration of $71 as finders' fees in connection with the Securities Purchase Agreements. b. Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,872 units at a purchase price of $4.44 per unit for total consideration of $1,464. Each unit consisted of one share of the Company’s common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, the Leading Investor, who purchased 33,784 of the units, was granted the right to maintain its percentage of the shares of the Company’s common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company’s outstanding common stock. In addition, such investor’s warrants contained full ratchet anti-dilution protection and cashless exercise provisions not contained in the other investors’ warrants. The other terms of the Leading Investor’s Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to certain Warrants, and the removal of the full ratchet anti-dilution protection see note 6. c. On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A, valued at approximately $629 at the day of the transaction. The Company exercised the option in February 2013. See also note 3. d. On e. On December 24, 2013, the Company entered into a Placement Agency Agreement with the Placement Agent, pursuant to which the Placement Agent agreed to use its reasonable best efforts to arrange for the sale of up to 1,580,000 shares of the Company’s common stock. In connection therewith, on December 24, 2013, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 1,580,000 shares of common stock, at a price of $10.00 per share, to two institutional investors in a registered direct offering (the "Offering"). The net proceeds to the Company from the Offering were approximately $14,887, after deducting Placement Agent's commissions of $816 and other offering expenses of the Company. f. On November 3, 2014, the Company entered into a Stock Purchase Agreement with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. (the “Investor”), pursuant to which the Company issued to the Investor an aggregate of 696,378 shares of common stock, at a price of $7.18 per share, which was equal to the closing price of the Company’s common stock on the Nasdaq Capital Market on October 31, 2014, for aggregate gross proceeds of approximately $5,000. The net proceeds to the Company from the offering were approximately $4,833, after deducting a finder's fee of $150 and other offering expenses of the Company. The offering closed on November 28, 2014. g. On April 2, 2015, the Company entered into an at the market issuance sales agreement (the “Sales Agreement”) with MLV & Co. LLC (“MLV”) pursuant to which the Company may issue and sell shares of its common stock having an aggregate offering price of up to $25,000 from time to time, at its option, through MLV as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3. The Company will pay MLV a commission of 3.0% of the gross proceeds of the sale of any shares sold through MLV. To date, no shares have been sold under the Sales Agreement. h. On June 4, 2015, the Company entered into a letter of agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“HCW”), pursuant to which HCW agreed to serve as exclusive agent, advisor or underwriter in any offering of the Company occurring between June 4, 2015 and July 4, 2015. On June 5, 2015, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell, in a registered direct offering (the “June 2015 Offering”): (1) an aggregate of 714,286 shares (the “Shares”) of the Company’s common stock at a price of $7.50 per Share to six investors (the “Purchasers”) and (2) at the option of each Purchaser (the “Overallotment Right”), additional shares of the Company’s common stock (the “Overallotment Shares”) up to the number equal to the number of Shares purchased by such Purchaser and at a price of $10.00 per Overallotment Share. The closing of the sale of the Shares occurred on June 10, 2015. The Overallotment Right shall be exercisable beginning December 10, 2015, and shall remain exercisable until December 10, 2016. Pursuant to the Engagement Letter, HCW received, for its services in the June 2015 Offering, a fee equal to 7% of the gross proceeds raised in the June 2015 Offering and an expense allowance of 1% of the gross proceeds raised in the June 2015 Offering, and affiliates of HCW received warrants to purchase 28,571 shares of common stock of the Company, exercisable immediately and expires after a period of three years and with an exercise price of $10.00 per share. The net proceeds to the Company from the June 2015 Offering were approximately $4,880, after deducting HCW’s expenses and other offering expenses of the Company totaling $478. i. As of August 31, 2015, the Company had outstanding warrants exercisable for 981,940 shares of common stock at exercise prices ranging from $3.7656 to $10.00 expiring at various dates between November 11, 2015 and June 10, 2018. The following table presents the warrant activity for the years ended August 31, 2015, 2014 and 2013: 2015 2014 2013 Warrants Weighted- Warrants Weighted- Price Warrants Weighted- Price* Warrants outstanding as of September 1 953,369 $ 5.15 1,215,034 $ 5.33 883,191 $ 5.56 Issued 28,571 $ 10.00 - - 353,285 $ 4.79 Exercised - - (261,665 ) $ 6.00 (21,442 ) $ 6.00 Warrants outstanding as of August 31 981,940 $ 5.29 953,369 $ 5.15 1,215,034 $ 5.33 Warrants exercisable as of August 31 981,496 $ 5.29 952,258 $ 5.15 1,213,478 $ 5.33 * See note 6 with regards to the amendment of price of certain warrants during the year ended August 31, 2013.

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Aug. 31, 2015
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	NOTE 10 - STOCK BASED COMPENSATION: As of August 31, 2015, the Company has one stock option plan, the Amended and Restated 2008 Stock Incentive Plan, under which, the Company had reserved a pool of 1,400,000 shares of the Company’s common stock which may be issued at the discretion of the Company’s Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The expected term is the length of time until the expected dates of exercising the options, and is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior. The following are the significant stock options transactions with executives and board members made during the years ended August 31, 2015, 2014 and 2013: a. On December 20, 2012, options to purchase 20,000 shares of the Company were granted to a director at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vested in two equal annual installments, commencing January 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $41, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years. b. On April 9, 2014, options to purchase an aggregate of 94,268 shares of the Company were granted to the CEO and to the CTO, both related parties, at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vested with respect to 31,420 shares of common stock on April 30, 2014, and the remaining shares of common stock vested in eight equal monthly installments of 7,586 each. These options expire on April 9, 2024. The fair value of these options on the date of grant was $781, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.21 years. c. On April 9, 2014, options to purchase an aggregate of 52,376 shares of the Company were granted to four members of the Company’s Board of Directors at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vested in two equal installments, on July 1, 2014 and January 1, 2015, and expire on April 9, 2024. The fair value of these options on the date of grant was $435, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.21 years. d. On April 9, 2014, options to purchase an aggregate of 2,556 shares of the Company were granted to an employee of the Subsidiary at an exercise price of $12.45 per share (equivalent to the traded market price on the date of grant). The options vested in four equal quarterly installments commencing on May 1, 2014, and expire on April 9, 2024. The fair value of these options on the date of grant was $21, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82.06%; risk-free interest rates of 1.65%; and expected term of 5.21 years. e. On November 13, 2014, the Company granted a total of 19,576 restricted stock units (“RSUs”) representing a right to receive shares of the Company’s common stock to the CEO, and the Company’s CTO, both related parties. The RSUs vested in two equal installments, each of 9,788 shares, on November 30 and December 31, 2014. The total fair value of these RSUs on the date of grant was $135, using the quoted closing market share price of $6.90 on the Nasdaq Capital Market on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2015, a total of 19,576 RSUs were vested and outstanding. f. On November 13, 2014, the Company granted a total of 10,872 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors. The RSUs vested on January 1, 2015. The total fair value of these RSUs on the date of grant was $75, using the quoted closing market share price of $6.90 on the Nasdaq Capital Market on the date of grant. g. On February 23, 2015, the Company granted a total of 159,696 RSUs representing a right to receive shares of the Company’s common stock to the Company’s CEO and the CTO, both related parties. The RSUs vest in 23 installments consisting of one installment of 13,308 shares on February 28, 2015 and 22 equal monthly installments of 6,654 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $728, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2015, a total of 53,232 RSUs were vested and outstanding. h. On February 23, 2015, the Company granted a total of 88,712 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors (22,178 RSUs to each director). The RSUs vest in two equal installments, each of 44,356 shares, on December 31, 2015 and December 31, 2016. The total fair value of these RSUs on the date of grant was $405, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. i. On February 23, 2015, the Company granted a total of 63,216 RSUs to three employees of the Subsidiary. The RSUs vest in 23 installments, consisting of one installment of 5,268 shares on February 28, 2015 and 22 equal monthly installments of 2,634 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $288, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. j. On April 1, 2015, the Company granted a total of 4,632 RSUs to an employee of the Subsidiary. The RSUs vest in 21 installments, consisting of one installment of 772 shares on April 30, 2015 and 20 equal monthly installments of 193 shares each, commencing May 31, 2015. The total fair value of these RSUs on the date of grant was $30, using the quoted closing market share price of $6.39 on the Nasdaq Capital Market on the date of grant. k. Options to employees, directors and non-employees. The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions: For options granted in the year ended August 31 2014 2013 Expected option life (years) 5.21 5.75-6 Expected stock price volatility (%) 82.06 64.35-75.46 Risk free interest rate (%) 1.65 0.92-1.01 Expected dividend yield (%) 0.0 0.0 No options were granted in 2015. A summary of the status of the stock options granted to employees and directors as of August 31, 2015, 2014 and 2013, and changes during the years ended on those dates, is presented below: Year ended August 31, 2015 2014 2013 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price $ $ $ Options outstanding at beginning of year 908,901 6.75 1,049,249 4.13 932,116 3.72 Changes during the year: Granted - at market price - - 149,200 12.45 100,800 7.88 Granted - above market price - - 24,667 6.00 Forfeited (3,297 ) 6.00 - - - - Exercised (1,370 ) 6.00 (289,548 ) 0.18 (8,334 ) 5.04 Options outstanding at end of year 904,234 6.75 908,901 6.75 1,049,249 4.13 Options exercisable at end of year 883,234 786,328 870,883 Weighted average fair value of options granted during the year - $ 8.31 $ 4.55 Costs incurred in respect of stock based compensation for employees and directors, for the years ended August 31, 2015, 2014 and 2013 were $278, $1,422 and $563, respectively. The total intrinsic value of employees options exercised during the year ended August 31, 2014 was $2,847. The options exercised during the year ended August 31, 2015, were at a price equal to the market price at the exercise date. The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2015: Range of exercise prices Number outstanding Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic value $ Years $ 4.08 to 6.00 510,234 5.68 4.94 394,440 6.48 to 7.88 244,800 4.72 7.06 - 12.45 149,200 8.61 12.45 - 904,234 5.90 6.75 394,440 The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2015: Range of exercise prices Number exercisable Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic value $ Years $ 4.08 to 6.00 510,234 5.68 4.94 394,440 6.48 to 7.88 223,800 4.45 6.98 - 12.45 149,200 8.61 12.45 - 883,234 5.86 6.73 394,440 As of August 31, 2015, there were $14 of unrecognized compensation costs related to non-vested options previously granted to employees and directors, to be recorded over the next 8 months. A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2015, 2014 and 2013, and changes during the years ended on this date, is presented below: Year ended August 31 2015 2014 2013 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price $ $ $ Options outstanding at beginning of year 62,221 7.13 79,689 7.21 79,689 7.21 Changes during the year: Exercised - - (17,468 ) 7.49 - - Expired (21,935 ) 6.82 - - - - Options outstanding at end of year 40,286 7.29 62,221 7.13 79,689 7.21 Options exercisable at end of year 36,119 53,888 47,469 The Company recorded stock based compensation of $3, $46 and $156 during the years ended August 31, 2015, 2014 and 2013, respectively, related to non-employees awards. The total intrinsic value of non-employees options exercised during the year ended August 31, 2014, was $187. None of the options were exercised by non-employees during the years ended August 31, 2015 and 2013. The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2015: Range of exercise prices Number outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate intrinsic value $ Years $ 6.00 23,618 4.90 6.00 - 9.12 16,668 3.36 9.12 - 40,286 4.26 7.29 - The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2015: Range of exercise prices Number exercisable Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic $ Years $ 4.08 to 6.00 19,451 4.78 6.00 - 9.12 16,668 3.36 9.12 - 36,119 4.13 7.44 - As of August 31, 2015 there were approximately $7 of unrecognized compensation costs related to non-vested non-employee options, to be recorded over the next 6 months. l. Restricted stock units The following table summarizes the activities for unvested RSUs granted to employees and directors for the year ended August 31, 2015: Number Unvested at the beginning of period - Granted 346,704 Vested and issued (33,488 ) Outstanding at the end of the period 313,216 Includes vested and unissued (see note 10g) 53,232 The Company recorded stock based compensation of $1,066 during the year ended August 31, 2015 related to RSU awards. As of August 31, 2015 there were $594 of unrecognized compensation costs related to RSUs, to be recorded over the next 16 months.

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Aug. 31, 2015
Financial Income and Expenses [Abstract]
Financial Income and Expenses	NOTE 11 - FINANCIAL INCOME AND EXPENSES a. Financial income Year ended August 31 2015 2014 2013 Gain on sale of marketable securities (note 3b) $ - $ 80 $ 90 Changes in fair value of warrants - - 44 Income from interest on deposits 160 138 19 Exchange rate differences - 7 - Income from interest on corporate bonds 8 - - Other - - 27 $ 168 $ 225 $ 180 b. Financial expenses Year ended August 31 2015 2014 2013 Exchange of warrants $ - $ - $ 297 Exchange rate differences 3 - 3 Bank commissions 9 11 13 Other 6 - - $ 18 $ 11 $ 313

Taxes on Income

Taxes on Income	12 Months Ended
	Aug. 31, 2015
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 12 - TAXES ON INCOME: Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary. a. Corporate taxation in the U.S. The applicable corporate tax rate for the Company is 35%. As of August 31, 2015, the Company has an accumulated tax loss carryforward of approximately $7,569 (as of August 31, 2014, approximately $6,791). Under U.S. tax laws, subject to certain limitations, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carryforward will expire in the years 2025 through 2032. b. Corporate taxation in Israel: The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2015 and 2014 is 26.5%. As of August 31, 2015, the Subsidiary has an accumulated tax loss carryforward of approximately $11,701 (as of August 31, 2014, approximately $9,487). Deferred income taxes: August 31 2015 2014 2013 In respect of: Net operating loss carryforward $ 5,750 $ 4,890 $ 3,993 Research and development expenses 906 688 339 Less - valuation allowance (6,656 ) (5,578 ) (4,332 ) Net deferred tax assets $ - $ - $ - Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance. c. Loss before taxes on income and income taxes included in the income statements of operations: Year ended 2015 2014 2013 Loss before taxes on income: U.S. $ 1,226 $ 893 $ 1,186 Outside U.S. 6,006 4,799 3,251 $ 7,232 $ 5,692 $ 4,437 Income tax expenses (benefit): Current: U.S. - - (13 ) Outside U.S. (1 ) 4 (192 ) $ (1 ) $ 4 $ (205 ) d. Reconciliation of the statutory tax benefit to effective tax expense Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense: Year ended 2015 2014 2013 Loss before income taxes as reported in the consolidated statement of comprehensive income (loss) $ (7,232 ) $ (5,692 ) $ (4,437 ) Statutory tax benefit (2,531 ) (1,992 ) (1,552 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax 1,599 1,104 902 Disallowable deductions 422 480 374 510 408 276 Uncertain tax position (1 ) 4 (205 ) Taxes on income for the reported year $ (1 ) $ 4 $ (205 ) e. Uncertainty in Income Taxes Accounting Standards Codification No. 740 “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. For the three years ended August 31, 2015, the Company did not record any amount for penalties related to tax contingencies. The following table summarizes the activity of the Company unrecognized tax benefits: Year ended August 31 2015 2014 2013 Balance at Beginning of Year $ 27 $ 23 228 Increase (decrease) in uncertain tax positions for the current year (1 ) 4 (205 ) Balance at End of Year $ 26 $ 27 $ 23 The decrease in uncertain tax positions for the year ended August 31, 2015, is a result of decreased accrual for uncertain tax position. The Company does not expect unrecognized tax expenses to change significantly over the next 12 months. The Company is subject to U.S. Federal income tax examinations for the tax years of 2010 through 2015. The Subsidiary is subject to Israeli income tax examinations for the tax years of 2011 through 2015. f. Valuation Allowance Rollforward Year ended Balance at beginning of period Additions Balance at end of period Allowance in respect of carryforward tax losses: Year ended August 31, 2015 $ 5,578 $ 1,078 $ 6,656 Year ended August 31, 2014 $ 4,332 $ 1,246 $ 5,578 Year ended August 31, 2013 $ 3,208 $ 1,124 $ 4,332

Related Parties - Transactions

Related Parties - Transactions	12 Months Ended
	Aug. 31, 2015
Related Parties - Transactions [Abstract]
RELATED PARTIES - TRANSACTIONS	NOTE 13 - RELATED PARTIES - TRANSACTIONS: a. During each of the fiscal years of 2015, 2014 and 2013 the Company paid to directors $47, $40 and $39, respectively, as directors fees. b. On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the CEO, whereby the CEO and the CTO, through KNRY, provide services to the Group (the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid a gross amount of NIS 50,400 per month for each of the CEO and CTO ($14) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements. On July 17, 2013, the Subsidiary entered into amendments to the Consulting Agreements with KNRY, according to which, the CEO's and CTO's annual payment was set at $250 and $200, respectively, calculated at an exchange rate of NIS 3.6 per U.S. dollar, and in addition to such payment they were granted the use of a company car and certain cash bonus payments, effective July 1, 2013. On February 24, 2014, the compensation committee of the Company's Board of Directors approved payment of cash bonuses to the CEO and the CTO in the amounts of $120 and $65, respectively. On March 18, 2014, the compensation committee of the Company's Board of Directors approved a temporary increase of nearly $7 per month for a specific period in which the CEO stayed in the United States. This payment replaced per diem payments for that business travel. On November 13, 2014, the Subsidiary entered into an amendment to the Consulting Agreements (the “Amendment Agreement”), according to which, the CEO and the CTO made some representations with regards to their relationship with KNRY and agreed to indemnify the Subsidiary in certain circumstances as defined in the amendment, among other revisions. On July 1, 2015, the compensation committee of the Company's Board of Directors approved an increase of six percent to the annual payment of the CEO and the CTO effective July 1, 2015. On July 16, 2015, the compensation committee of the Company's Board of Directors approved payment of cash bonuses to the CEO and the CTO in the amounts three monthly consulting fee. c. Balances with related parties: August 31 2015 2014 Receivable $ - $ 330 Accounts payable and accrued expenses - KNRY $ 36 $ 47 The receivable is the withholding tax from options exercised on August 1, 2014 which was received by the Company on September 12, 2014. d. Expenses to related parties: Year ended August 31 2015 2014 2013 KNRY $ 586 $ 671 $ 448

Subsequent Event

Subsequent Event	12 Months Ended
	Aug. 31, 2015
Subsequent Event [Abstract]
SUBSEQUENT EVENT	NOTE 14 - SUBSEQUENT EVENT On October 22, 2015, the Company, the Subsidiary and HLST amended the LoI, dated July 3, 2015 (as described in note 1a1) by revising the schedule of payments and extending the no-shop period until December 22, 2015. The total payments to be made by HLST remains $50,000, as initially agreed. According to the revised schedule of payments under the license, $11,000 would be paid up front and $26,500 would be payable upon achievement of certain milestones and conditions.

Significant Accounting Polici21

Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2015
Significant Accounting Policies [Abstract]
General	a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the “Subsidiary”). On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware. On July 3, 2015, the Company and the Subsidiary entered into a non-binding Letter of Intent (the “LoI”) with Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co., Ltd. (“HLST” and together - “Sinopharm-HLST”), according to which, the Company will enter into a Stock Purchase Agreement with Sinopharm-HLST pursuant to which Sinopharm-HLST will agree to buy and the Company will agree to sell an aggregate of 1,155,367 shares of its common stock, or the Shares, at a price per Share of approximately $10.39 (and $12,000 in total), and in addition, the Subsidiary will grant a commercialization license in the territory of Peoples Republic of China (the “Territory”) related to oral insulin, for an aggregate of approximately $38,000, of which $18,000 would be paid up front, and $20,000 would be payable upon achievement of a certain milestone, and royalties of 10% on net sales of the related commercialized products to be sold by Sinopharm-HLST in the Territory. In July 2015, according to the LoI, Sinopharm-HLST paid the Subsidiary a non-refundable amount of $500 as a no-shop fee, and the Company and the Subsidiary committed to negotiate exclusively with Sinopharm-HLST regarding an out-licensing and commercialization transaction in the Territory. In the event that the parties enter into a license agreement, the foregoing amount will be deducted from the initial payment due by Sinopharm-HLST to the Subsidiary. The no-shop fee is presented as an advance on account of the license agreement among current liabilities, and is not to be carried to income prior to the recognition of such additional future payments from entering the license agreement. The Company will evaluate the accounting treatment of the agreement once the agreement will be signed and agreed by the parties. See also note 14 as to the amendment to the LoI signed in October 2015. 2) Development and liquidity risks The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities. Based on its current cash resources and commitments, and cash received in private and public offerings in the years ended August 31, 2015 and 2014, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond after the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.
Accounting principles	b. Accounting principles The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Use of estimates in the preparation of financial statements	c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation.
Functional currency	d. Functional currency The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
Principles of consolidation	e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
Income taxes	f. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities. Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
Research and development, net	g. Research and development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately. Grants received from the Office of Chief Scientist (“OCS”) and from the Bio-Jerusalem fund (“Bio-Jerusalem”) are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 8(i) and 8(j).
Cash equivalents	h. Cash equivalents The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Loss per common share	i. Loss per common share Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and restricted stock units excluded from the calculation of diluted net loss was 2,953,962 for the year ended August 31, 2015 (1,924,491 and 2,343,972 for the years ended August 31, 2014 and 2013, respectively).
Stock based compensation	j. Stock based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The fair value of share based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The expected service period is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior. The forfeitures are estimated based on historical experience and anticipated future conditions. The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.
Fair value measurement	k. Fair value measurement: Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. As of August 31, 2015, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1). In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. As of August 31, 2015, the carrying amount of cash and cash equivalents, short term deposits, prepaid expenses and other current assets and accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments. As of August 31, 2015, the carrying amount of long term deposits approximates their fair values due to the stated interest rates which approximate market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.
Marketable securities	l. Marketable securities 1) Available-for-sale securities Available-for-sale equity securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses. 2) Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, management assesses whether there are any indicators that the value of the Company’s marketable securities may be impaired, which includes reviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and duration of the decline. In the Company’s evaluation, the Company considers its ability and intent to hold these investments for a reasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair value of the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To the extent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimated fair value in the security.
Concentration of credit risks	m. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long term deposits and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.
Property and equipment	n. Property and equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets. Annual rates of depreciation are as follows: % Computers and peripheral equipment 33 Office furniture and equipment 15-33 Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Significant Accounting Polici22

Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2015
Significant Accounting Policies [Abstract]
Schedule of estimated useful lives	% Computers and peripheral equipment 33 Office furniture and equipment 15-33

Short Term Deposits (Tables)

Short Term Deposits (Tables)	12 Months Ended
	Aug. 31, 2015
Short Term Deposits/ Long Term Deposits [Abstract]
Schedule of short term debt	August 31 2015 2014 Annual interest rate Amount Annual interest rate Amount Dollar deposits 0.3-1.52 % $ 11,928 0.12-0.6 % $ 18,481

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Aug. 31, 2015
Marketable Securities [Abstract]
Schedule of marketable securities include investments in equity securities	August 31 2015 2014 Short term: D.N.A (see b below) $ 1,153 $ 1,047 Held to maturity bonds (see c below) 935 - $ 2,088 $ 1,047 Long term: Held to maturity bonds (see c below) $ 940 $ -
Schedule of amortized cost and estimated fair value of held-to-maturity securities	August 31, 2015 Amortized cost Gross unrealized losses Estimated fair value Short term: Commercial bonds $ 914 $ 1 $ 913 Accrued interest 21 - 21 Long term 940 3 937 $ 1,875 $ 4 $ 1,871

Long Term Deposits (Tables)

Long Term Deposits (Tables)	12 Months Ended
	Aug. 31, 2015
Short Term Deposits/ Long Term Deposits [Abstract]
Schedule of long-term investment	August 31 2015 2014 Bank deposits (1) $ 8,017 $ - Lease car deposits 4 2 Investment 1 1 $ 8,022 $ 3 (1) Represents U.S. dollar bank deposits which carry fixed annual interest rates between 1.28% to 1.64%, with maturities of more than one year from August 31, 2015. The latest maturity date is during the year ending August 31, 2017.

Property and Equipment Net (Tab

Property and Equipment Net (Tables)	12 Months Ended
	Aug. 31, 2015
Property and Equipment Net [Abstract]
Schedule of property and equipment	August 31 2015 2014 Cost: Leasehold improvements $ 78 $ 78 Office furniture and equipment 29 28 Computers and peripheral equipment 38 38 145 144 Less - accumulated depreciation and amortization 134 130 $ 11 $ 14

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Aug. 31, 2015
Warrants [Abstract]
Schedule of fair value measurements estimated utilizing Level 3 inputs	Year ended August 31, 2013 Carrying value at the beginning of the period $ 637 Additions 28 Changes in fair value (44 ) Exchange of warrants (621 ) Carrying value at the end of the period $ -

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Aug. 31, 2015
Stockholders' Equity [Abstract]
Schedule of Warrant Activity	2015 2014 2013 Warrants Weighted- Warrants Weighted- Price Warrants Weighted- Price* Warrants outstanding as of September 1 953,369 $ 5.15 1,215,034 $ 5.33 883,191 $ 5.56 Issued 28,571 $ 10.00 - - 353,285 $ 4.79 Exercised - - (261,665 ) $ 6.00 (21,442 ) $ 6.00 Warrants outstanding as of August 31 981,940 $ 5.29 953,369 $ 5.15 1,215,034 $ 5.33 Warrants exercisable as of August 31 981,496 $ 5.29 952,258 $ 5.15 1,213,478 $ 5.33 * See note 6 with regards to the amendment of price of certain warrants during the year ended August 31, 2013.

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Aug. 31, 2015
Stock Based Compensation [Abstract]
Schedule of fair value of option grant using the Black Scholes option-pricing model	For options granted in the year ended August 31 2014 2013 Expected option life (years) 5.21 5.75-6 Expected stock price volatility (%) 82.06 64.35-75.46 Risk free interest rate (%) 1.65 0.92-1.01 Expected dividend yield (%) 0.0 0.0
Schedule of stock options granted to employees and directors	Year ended August 31, 2015 2014 2013 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price $ $ $ Options outstanding at beginning of year 908,901 6.75 1,049,249 4.13 932,116 3.72 Changes during the year: Granted - at market price - - 149,200 12.45 100,800 7.88 Granted - above market price - - 24,667 6.00 Forfeited (3,297 ) 6.00 - - - - Exercised (1,370 ) 6.00 (289,548 ) 0.18 (8,334 ) 5.04 Options outstanding at end of year 904,234 6.75 908,901 6.75 1,049,249 4.13 Options exercisable at end of year 883,234 786,328 870,883 Weighted average fair value of options granted during the year - $ 8.31 $ 4.55
Schedule of options granted to employees and directors outstanding and exercisable	Range of exercise prices Number outstanding Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic value $ Years $ 4.08 to 6.00 510,234 5.68 4.94 394,440 6.48 to 7.88 244,800 4.72 7.06 - 12.45 149,200 8.61 12.45 - 904,234 5.90 6.75 394,440 Range of exercise prices Number exercisable Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic value $ Years $ 4.08 to 6.00 510,234 5.68 4.94 394,440 6.48 to 7.88 223,800 4.45 6.98 - 12.45 149,200 8.61 12.45 - 883,234 5.86 6.73 394,440
Schedule of stock options granted to non-employees outstanding	Year ended August 31 2015 2014 2013 Number of options Weighted average exercise price Number of options Weighted average exercise price Number of options Weighted average exercise price $ $ $ Options outstanding at beginning of year 62,221 7.13 79,689 7.21 79,689 7.21 Changes during the year: Exercised - - (17,468 ) 7.49 - - Expired (21,935 ) 6.82 - - - - Options outstanding at end of year 40,286 7.29 62,221 7.13 79,689 7.21 Options exercisable at end of year 36,119 53,888 47,469
Schedule of concerning the options granted to non-employees outstanding and exercisable	Range of exercise prices Number outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate intrinsic value $ Years $ 6.00 23,618 4.90 6.00 - 9.12 16,668 3.36 9.12 - 40,286 4.26 7.29 - Range of exercise prices Number exercisable Weighted Average Remaining Contractual Life Weighted average exercise price Aggregate intrinsic $ Years $ 4.08 to 6.00 19,451 4.78 6.00 - 9.12 16,668 3.36 9.12 - 36,119 4.13 7.44 -
Schedule of activities for unvested RSUs granted to employees and directors	Number Unvested at the beginning of period - Granted 346,704 Vested and issued (33,488 ) Outstanding at the end of the period 313,216 Includes vested and unissued (see note 10g) 53,232

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Aug. 31, 2015
Financial Income and Expenses [Abstract]
Schedule of financial income	Year ended August 31 2015 2014 2013 Gain on sale of marketable securities (note 3b) $ - $ 80 $ 90 Changes in fair value of warrants - - 44 Income from interest on deposits 160 138 19 Exchange rate differences - 7 - Income from interest on corporate bonds 8 - - Other - - 27 $ 168 $ 225 $ 180
Schedule of financial expenses	Year ended August 31 2015 2014 2013 Exchange of warrants $ - $ - $ 297 Exchange rate differences 3 - 3 Bank commissions 9 11 13 Other 6 - - $ 18 $ 11 $ 313

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Aug. 31, 2015
Taxes on Income [Abstract]
Schedule of deferred income taxes	August 31 2015 2014 2013 In respect of: Net operating loss carryforward $ 5,750 $ 4,890 $ 3,993 Research and development expenses 906 688 339 Less - valuation allowance (6,656 ) (5,578 ) (4,332 ) Net deferred tax assets $ - $ - $ -
Schedule of income taxes included in the income statements	Year ended 2015 2014 2013 Loss before taxes on income: U.S. $ 1,226 $ 893 $ 1,186 Outside U.S. 6,006 4,799 3,251 $ 7,232 $ 5,692 $ 4,437 Income tax expenses (benefit): Current: U.S. - - (13 ) Outside U.S. (1 ) 4 (192 ) $ (1 ) $ 4 $ (205 )
Schedule of reconciliation of income taxes	Year ended 2015 2014 2013 Loss before income taxes as reported in the consolidated statement of comprehensive income (loss) $ (7,232 ) $ (5,692 ) $ (4,437 ) Statutory tax benefit (2,531 ) (1,992 ) (1,552 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax 1,599 1,104 902 Disallowable deductions 422 480 374 510 408 276 Uncertain tax position (1 ) 4 (205 ) Taxes on income for the reported year $ (1 ) $ 4 $ (205 )
Schedule of unrecognized tax benefits activity	Year ended August 31 2015 2014 2013 Balance at Beginning of Year $ 27 $ 23 228 Increase (decrease) in uncertain tax positions for the current year (1 ) 4 (205 ) Balance at End of Year $ 26 $ 27 $ 23
Schedule of valuation allowance rollforward	Year ended Balance at beginning of period Additions Balance at end of period Allowance in respect of carryforward tax losses: Year ended August 31, 2015 $ 5,578 $ 1,078 $ 6,656 Year ended August 31, 2014 $ 4,332 $ 1,246 $ 5,578 Year ended August 31, 2013 $ 3,208 $ 1,124 $ 4,332

Related Parties - Transactions

Related Parties - Transactions (Tables)	12 Months Ended
	Aug. 31, 2015
Related Parties - Transactions [Abstract]
Schedule of Balances with Related Parties	August 31 2015 2014 Receivable $ - $ 330 Accounts payable and accrued expenses - KNRY $ 36 $ 47
Schedule of Related Party Expens	Year ended August 31 2015 2014 2013 KNRY $ 586 $ 671 $ 448

Significant Accounting Polici33

Significant Accounting Policies (Details)	Aug. 31, 2015
Computers and peripheral equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated life of useful lives percentage	33.00%
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated life of useful lives percentage	33.00%
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated life of useful lives percentage	15.00%

Significant Accounting Polici34

Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 03, 2015	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Significant Accounting Policies (Textual)
Aggregate of common stock shares, value			$ 14,887
Calculation of diluted net loss		2,953,962	1,924,491	2,343,972
Sinopharm-HLST [Member]
Significant Accounting Policies (Textual)
Aggregate of common stock shares, value	$ 12,000
Aggregate of common stock shares	1,155,367
Common stock price per share	$ 10.39
Aggregate of value of additional subsidary	$ 38,000
Common stock held by subsidiary paid in front	18,000
Common stock held by subsidiary payable upon achievement	20,000
Nonrefundable subsidiary amount	$ 0
Royalties percentage on net sales	10.00%

Short Term Deposits (Details)

Short Term Deposits (Details) - Dollar Deposits [Member] - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Short-term Debt [Line Items]
Short term deposits	$ 11,928	$ 18,481
Minimum [Member]
Short-term Debt [Line Items]
Annual interest rate	0.30%	0.12%
Maximum [Member]
Short-term Debt [Line Items]
Annual interest rate	1.52%	0.60%

Short Term Deposits (Details Te

Short Term Deposits (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Short Term Deposits (Textual)
Purchased short term deposits	$ 13,123	$ 55,750
Proceeds from sale of short term deposits	$ 19,701	$ 42,539

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Short term:
D.N.A (see b below)	$ 1,153	$ 1,047
Held to maturity bonds (see c below)	935
Marketable securities	2,088	$ 1,047
Long term:
Held to maturity bonds (see c below)	$ 940

Marketable Securities (Details

Marketable Securities (Details 1) $ in Thousands	12 Months Ended
	Aug. 31, 2015USD ($)
Marketable Securities, Current [Abstract]
Maturity securities amortized cost	$ 1,875
Maturity securities gross unrealized losses	4
Maturity securities estimated fair value	1,871
Long term [Member]
Marketable Securities, Current [Abstract]
Maturity securities amortized cost	940
Maturity securities gross unrealized losses	3
Maturity securities estimated fair value	937
Accrued interest [Member] | Short term [Member]
Marketable Securities, Current [Abstract]
Maturity securities amortized cost	$ 21
Maturity securities gross unrealized losses
Maturity securities estimated fair value	$ 21
Commercial bonds [Member] | Short term [Member]
Marketable Securities, Current [Abstract]
Maturity securities amortized cost	914
Maturity securities gross unrealized losses	1
Maturity securities estimated fair value	$ 913

Marketable Securities (Detail39

Marketable Securities (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2013	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Marketable Securities (Textual)
Number of shares sold	1,750,000		2,625,989	5,250,000
Total consideration	$ 56		$ 138	$ 170
Percentage of ownership interest		9.60%
Cost of securities		$ 590	590
Amount reclassified to earnings			$ (80)	$ (90)
Marketable securities		$ 940
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates		1.31%
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates		0.57%

Long Term Deposits (Details)

Long Term Deposits (Details) - USD ($) $ in Thousands		Aug. 31, 2015	Aug. 31, 2014
Short Term Deposits/ Long Term Deposits [Abstract]
Bank deposits (1)	[1]	$ 8,017
Lease car deposits		4	$ 2
Investment		1	1
Total long term deposits and investment		$ 8,022	$ 3
[1]	Represents U.S. dollar bank deposits which carry fixed annual interest rates between 1.28% to 1.64%, with maturities of more than one year from August 31, 2015. The latest maturity date is during the year ending August 31, 2017.

Long Term Deposits (Details Tex

Long Term Deposits (Details Textual)	12 Months Ended
	Aug. 31, 2015
Long Term Deposits (Textual)
Maturity date	Aug. 31, 2017
Maximum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	1.64%
Minimum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	1.28%

Property and Equipment Net (Det

Property and Equipment Net (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment	$ 145	$ 144
Less - accumulated depreciation and amortization	134	130
Property and equipment, net	11	14
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	78	78
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	29	28
Computers and peripheral equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 38	$ 38

Property and Equipment Net (D43

Property and Equipment Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Property and Equipment Net (Textual)
Depreciation expenses	$ 4	$ 6	$ 5

Warrants (Details)

Warrants (Details) - Level 3 [Member]	12 Months Ended
	Aug. 31, 2013USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value at the beginning of the period	$ 637
Additions	28
Changes in fair value	(44)
Exchange of warrants	$ (621)
Carrying value at the end of the period

Warrants (Details Textual)

Warrants (Details Textual)	Nov. 29, 2012$ / sharesshares	Dec. 31, 2012Warrants$ / sharesshares	Nov. 30, 2012$ / shares	Aug. 31, 2012$ / sharesshares	Dec. 31, 2011Warrants$ / sharesshares	Nov. 30, 2012USD ($)	Aug. 31, 2015USD ($)shares
Warrant (Textual)
Purchase of warrants, Shares							981,940
CEO [Member]
Warrant (Textual)
Fair value of warrants | $							$ 168
Aggregate number in excess of shares							137,311
Number of shares authorized by warrant							112,690
Warrant [Member]
Warrant (Textual)
Fair value of warrants | $							$ 145
Financial expense | $						$ 297
Expected dividend yield						0.00%
Expected term						4 years
Expected volatility						62.29%
Risk-free interest rate						0.57%
Private Placement [Member]
Warrant (Textual)
Number of warrants | Warrants		3			3
Purchase of warrants, Shares		311,797			311,797
Additional warrant issued	137,311
Exercise price | $ / shares	$ 7.20	$ 6	$ 3.7656	$ 3.7656	$ 6
Number of shares authorized by warrant				290,459

Employees Rights Upon Retirem46

Employees Rights Upon Retirement (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Employee Rights Upon Retirement [Abstract]
Severance pay insurance deposits	$ 2	$ 2	$ 2
Severance pay expenses	26	26	23
Severance pay expenses in respect of Contribution Plan	24	$ 26	$ 13
Severance pay expected deposit	$ 26

Commitments (Details)

Commitments (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 01, 2015	May. 13, 2014	Nov. 04, 2013	Jul. 11, 2013	Mar. 31, 2011	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Long-term Purchase Commitment [Line Items]
Shares issued for services rendered						$ 93	$ 102	$ 244
Total revenue						$ 2,194
Office Building [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term						36 months
Annual lease payments 2015						$ 23
Annual lease payments 2016						23
Annual lease payments 2017						2
Lease expenses						$ 23	27	13
Vehicles [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term						3 years
Annual lease payments 2016						$ 15
Annual lease payments 2017						9
Lease expenses						16	$ 28	30
Deposit for lease						$ 4
Bio Jerusalem [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage						4.00%
Royalty percentage maximum percentage of grants received						100.00%
Grants receivable						$ 65
Grants received						12
Chief Scientist Office [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received							100.00%
Grants received						$ 49	$ 428	$ 297
Chief Scientist Office [Member] | Minimum [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received						3.00%
Chief Scientist Office [Member] | Maximum [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage maximum percentage of grants received						3.50%
Entera Bio [Member] | D.N.A. [Member]
Long-term Purchase Commitment [Line Items]
Principal amount of promissory note received					$ 450
Interest rate					0.45%
Ownership percentage retained					3.00%
Ordinary shares received					8,404,667
Royalty percentage					3.00%
Hadasit [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services						$ 200
Consultant [Member]
Long-term Purchase Commitment [Line Items]
Royalty percentage						8.00%
Capitalized cost						$ 113
Commitments for consulting service, monthly fixed fee						8
Options granted					20,834
Options granted, exercise price					$ 6
Vesting period					5 years
Consulting services						$ 111
Dividend yield						0.00%
Expected term						5 years 5 months 16 days
Expected volatility						81.06%
Risk-free interest rate						1.94%
Advisor [Member]
Long-term Purchase Commitment [Line Items]
Shares issued for services	3,750		10,000	5,000		15,000	15,000
Shares authorized for issuance for services	15,000	15,000
Shares issued for services rendered	$ 24		$ 64	$ 35		$ 107
Clinical Research Organization Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services						3,290
Consulting services						1,318
Commitments for bonus payments upon achieving certain milestones						280
First Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Shares issued for services rendered						102
Commitments for bonus payments upon achieving certain milestones						600
Second Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Shares issued for services rendered						217
Third Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services						311
Shares issued for services rendered						550
Fourth Master Service Agreement [Member]
Long-term Purchase Commitment [Line Items]
Commitments for consulting services						40
Shares issued for services rendered						$ 430

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Warrants
Warrants outstanding as of August 31	953,369	1,215,034	883,191
Issued	28,571		353,285
Exercised		(261,665)	(21,442)
Warrants outstanding as of August 31	981,940	953,369	1,215,034
Warrants exercisable as of August 31	981,496	952,258	1,213,478
Weighted-Average Exercise Price
Warrants outstanding as of September 1	$ 5.15	$ 5.33	$ 5.56	[1]
Issued	$ 10		4.79	[1]
Exercised		$ 6	6	[1]
Warrants outstanding as of August 31	$ 5.29	5.15	5.33
Warrants exercisable as of August 31	$ 5.29	$ 5.15	$ 5.33	[1]
[1]	See note 6 with regards to the amendment of price of certain warrants during the year ended August 31, 2013.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands

Jun. 05, 2015Investors$ / sharesshares

Jun. 04, 2015USD ($)$ / sharesshares

Apr. 02, 2015USD ($)

Nov. 03, 2014USD ($)$ / sharesshares

Jul. 10, 2013USD ($)$ / sharesshares

Dec. 24, 2013USD ($)$ / sharesshares

Sep. 30, 2012USD ($)shares

Aug. 31, 2012USD ($)$ / sharesshares

Nov. 30, 2012USD ($)$ / sharesshares

Aug. 31, 2015USD ($)$ / sharesshares

Aug. 31, 2014USD ($)

Aug. 31, 2013USD ($)

Stockholders Equity (Textual)

Aggregate of common stock shares, value

$ 14,887

Additional shares issued to investors

$ 93

102

$ 4,239

Net proceeds from offering

[1]

$ 9,713

$ 14,887

$ 5,715

Purchase of warrants, Shares | shares

981,940

Maximum [Member]

Stockholders Equity (Textual)

Warrant exercise price | $ / shares

$ 10

Investment Warrants Expiration Date

Jun. 10, 2018

Minimum [Member]

Stockholders Equity (Textual)

Warrant exercise price | $ / shares

$ 3.7656

Investment Warrants Expiration Date

Nov. 11, 2015

Investor [Member] | Securities Purchase Agreements [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares, value

$ 5,000

$ 3,560

$ 1,464

Aggregate of common stock shares | shares

696,378

5,652

801,942

329,872

Purchase price per share | $ / shares

$ 7.18

$ 4.44

$ 4.44

Warrant exercise price | $ / shares

$ 6

$ 6

Term of warrant

5 years

5 years

Warrant issued to purchase of common stock | shares

2,826

Proceeds from investment of shares and warrants

$ 25

Fees and Commissions

$ 150

$ 71

Common stock price | $ / shares

$ 0.50

Net proceeds from offering

$ 4,833

Leading Investor [Member] | Securities Purchase Agreements [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares | shares

225,226

33,784

Percentage on outstanding common stock

5.00%

5.00%

D.N.A. [Member] | Securities Purchase Agreements [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares, value

$ 629

Aggregate of common stock shares | shares

199,172

Number of option to purchase ordinary shares | shares

21,637,611

Aegis Capital Corp [Member] | Placement Agency Agreement [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares, value

$ 4,239

Aggregate of common stock shares | shares

658,144

Purchase price per share | $ / shares

$ 7

Fees and Commissions

$ 255

Placement Agent [Member] | Placement Agency Agreement [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares, value

$ 14,887

Aggregate of common stock shares | shares

1,580,000

Purchase price per share | $ / shares

$ 10

Fees and Commissions

$ 816

MLV [Member] | Sales Agreement [Member]

Stockholders Equity (Textual)

Net proceeds from offering

$ 25,000

Percentage of commission

3.00%

HCW [Member] | Securities Purchase Agreements [Member]

Stockholders Equity (Textual)

Aggregate of common stock shares | shares

714,286

Purchase price per share | $ / shares

$ 7.50

Common stock price | $ / shares

$ 10

Number of investor | Investors

6

Sale of stock, Description

The Overallotment Right shall be exercisable beginning December 10, 2015, and shall remain exercisable until December 10, 2016. Pursuant to the Engagement Letter, HCW received, for its services in the June 2015 Offering, a fee equal to 7% of the gross proceeds raised in the June 2015 Offering and an expense allowance of 1% of the gross proceeds raised in the June 2015 Offering.

HCW [Member] | Engagement Letter [Member]

Stockholders Equity (Textual)

Warrant exercise price | $ / shares

$ 10

Term of warrant

3 years

Warrant issued to purchase of common stock | shares

28,571

Fees and Commissions

$ 478

Net proceeds from offering

$ 4,880

[1]

See notes 9b, 9d, 9e, 9f and 9h.

Stock Based Compensation (Detai

Stock Based Compensation (Details) - Options granted [Member]	12 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)	5 years 2 months 16 days
Expected stock price volatility (%)	82.06%
Risk free interest rate (%)	1.65%
Expected dividend yield (%)	0.00%	0.00%
Maximum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)		6 years
Expected stock price volatility (%)		75.46%
Risk free interest rate (%)		1.01%
Minimum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)		5 years 9 months
Expected stock price volatility (%)		64.35%
Risk free interest rate (%)		0.92%

Stock Based Compensation (Det51

Stock Based Compensation (Details 1) - $ / shares	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Employee [Member]
Number of options
Options outstanding at beginning of year	908,901	1,049,249	932,116
Changes during the year:
Granted - at market price		149,200	100,800
Granted - above market price			24,667
Forfeited	(3,297)
Exercised	(1,370)	(289,548)	(8,334)
Options outstanding at end of year	904,234	908,901	1,049,249
Options exercisable at end of year	883,234	786,328	870,883
Weighted average fair value of options granted during the year		$ 8.31	$ 4.55
Weighted average exercise price
Options outstanding at beginning of year	$ 6.75	4.13	3.72
Changes during the year:
Granted - at market price		$ 12.45	7.88
Granted - above market price			$ 6
Forfeited	$ 6
Exercised	6	$ 0.18	$ 5.04
Options outstanding at end of year	$ 6.75	$ 6.75	$ 4.13
Non Employees [Member]
Number of options
Options outstanding at beginning of year	62,221	79,689	79,689
Changes during the year:
Expired	(21,935)
Exercised		(17,468)
Options outstanding at end of year	40,286	62,221	79,689
Options exercisable at end of year	36,119	53,888	47,469
Weighted average exercise price
Options outstanding at beginning of year	$ 7.13	$ 7.21	$ 7.21
Changes during the year:
Expired	$ 6.82
Exercised		$ 7.49
Options outstanding at end of year	$ 7.29	$ 7.13	$ 7.21

Stock Based Compensation (Det52

Stock Based Compensation (Details 2) $ / shares in Units, $ in Thousands	12 Months Ended
	Aug. 31, 2015USD ($)$ / sharesshares
Employee [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	904,234
Outstanding, weighted average remaining contractual life, years	5 years 10 months 24 days
Outstanding, weighted average exercise price	$ 6.75
Outstanding, aggregate intrinsic value | $	$ 394,440
Number exercisable | shares	883,234
Exercisable, weighted average remaining contractual life, years	5 years 10 months 10 days
Exercisable, weighted average exercise price	$ 6.73
Exercisable, aggregate intrinsic value | $	$ 394,440
Employee [Member] | $4.08 to 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	510,234
Outstanding, weighted average remaining contractual life, years	5 years 8 months 5 days
Outstanding, weighted average exercise price	$ 4.94
Outstanding, aggregate intrinsic value | $	$ 394,440
Number exercisable | shares	510,234
Exercisable, weighted average remaining contractual life, years	5 years 8 months 5 days
Exercisable, weighted average exercise price	$ 4.94
Exercisable, aggregate intrinsic value | $	$ 394,440
Employee [Member] | $6.48 to 7.88 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	244,800
Outstanding, weighted average remaining contractual life, years	4 years 8 months 19 days
Outstanding, weighted average exercise price	$ 7.06
Outstanding, aggregate intrinsic value | $
Number exercisable | shares	223,800
Exercisable, weighted average remaining contractual life, years	4 years 5 months 12 days
Exercisable, weighted average exercise price	$ 6.98
Exercisable, aggregate intrinsic value | $
Employee [Member] | $12.45 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	149,200
Outstanding, weighted average remaining contractual life, years	8 years 7 months 10 days
Outstanding, weighted average exercise price	$ 12.45
Outstanding, aggregate intrinsic value | $
Number exercisable | shares	149,200
Exercisable, weighted average remaining contractual life, years	8 years 7 months 10 days
Exercisable, weighted average exercise price	$ 12.45
Exercisable, aggregate intrinsic value | $
Non Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	40,286
Outstanding, weighted average remaining contractual life, years	4 years 3 months 4 days
Outstanding, weighted average exercise price	$ 7.29
Outstanding, aggregate intrinsic value | $
Number exercisable | shares	36,119
Exercisable, weighted average remaining contractual life, years	4 years 1 month 17 days
Exercisable, weighted average exercise price	$ 7.44
Exercisable, aggregate intrinsic value | $
Non Employees [Member] | $4.08 to 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number exercisable | shares	19,451
Exercisable, weighted average remaining contractual life, years	4 years 9 months 11 days
Exercisable, weighted average exercise price	$ 6
Exercisable, aggregate intrinsic value | $
Non Employees [Member] | 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	23,618
Outstanding, weighted average remaining contractual life, years	4 years 10 months 24 days
Outstanding, weighted average exercise price	$ 6
Outstanding, aggregate intrinsic value | $
Non Employees [Member] | 9.12 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	16,668
Outstanding, weighted average remaining contractual life, years	3 years 4 months 10 days
Outstanding, weighted average exercise price	$ 9.12
Outstanding, aggregate intrinsic value | $
Number exercisable | shares	16,668
Exercisable, weighted average remaining contractual life, years	3 years 4 months 10 days
Exercisable, weighted average exercise price	$ 9.12
Exercisable, aggregate intrinsic value | $

Stock Based Compensation (Det53

Stock Based Compensation (Details 3) - Restricted Stock Units (RSUs) [Member] - Employee [Member]	12 Months Ended
	Aug. 31, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at the beginning of period
Granted	346,704
Vested and issued	(33,488)
Outstanding at the end of the period	313,216
Includes vested and unissued (see note 10g)	53,232

Stock Based Compensation (Det54

Stock Based Compensation (Details Textual) $ / shares in Units, $ in Thousands	Apr. 01, 2015Installments$ / sharesshares	Feb. 23, 2015USD ($)Installments$ / sharesshares	Nov. 13, 2014USD ($)Installments$ / sharesshares	Apr. 09, 2014USD ($)Installments$ / sharesshares	Dec. 20, 2012USD ($)Installments$ / sharesshares	Aug. 31, 2015USD ($)$ / sharesshares	Aug. 31, 2014USD ($)$ / sharesshares	Aug. 31, 2013USD ($)$ / sharesshares
Stock-Based Compensation (Textual)
Stock based compensation | $						$ 1,347	$ 1,468	$ 719
Employee [Member]
Stock-Based Compensation (Textual)
Options granted							149,200	100,800
Options granted, exercise price | $ / shares							$ 12.45	$ 7.88
Stock based compensation | $						$ 278	$ 1,422	$ 563
Intrinsic value of options exercised | $							2,847
Unrecognized compensation expense | $						14
Non Employees [Member]
Stock-Based Compensation (Textual)
Stock based compensation | $						$ 3	46	$ 156
Intrinsic value of options exercised | $							$ 187
Unrecognized compensation expense | $						$ 7
Amended and Restated 2008 Stock Incentive Plan [Member]
Stock-Based Compensation (Textual)
Number of shares reserved for grant						1,400,000
Restricted stock units [Member]
Stock-Based Compensation (Textual)
Stock based compensation | $						$ 1,066
Unrecognized compensation expense | $						$ 594
Chief Executive Officer and CTO [Member]
Stock-Based Compensation (Textual)
Options vested in period				31,420
Options granted				94,268
Options granted, exercise price | $ / shares				$ 12.45
Number of vesting installments | Installments				8
Fair value of options granted | $				$ 781
Number of options to vest each installment				7,586
Expiration date				Apr. 9, 2024
Expected dividend yield				0.00%
Expected volatility				82.06%
Risk-free interest rate				1.65%
Expected term				5 years 2 months 16 days
Chief Executive Officer and CTO [Member] | Restricted stock units [Member]
Stock-Based Compensation (Textual)
Number of shares reserved for grant		159,696	19,576
Number of installments | Installments		23	2
Options vested in period			9,788
Vested and outstanding RSUs		53,232	19,576
Fair value of restricted stock units | $		$ 728	$ 135
Quoted closing market share price | $ / shares		$ 4.56	$ 6.90
Chief Executive Officer and CTO [Member] | Restricted stock units [Member] | One installment
Stock-Based Compensation (Textual)
Number of installments | Installments		1
Options vested in period		13,308
Chief Executive Officer and CTO [Member] | Restricted stock units [Member] | 22 equal monthly installments
Stock-Based Compensation (Textual)
Number of installments | Installments		22
Options vested in period		6,654
Board of Directors [Member]
Stock-Based Compensation (Textual)
Maximum term of the options						10 years
Options granted					20,000
Options granted, exercise price | $ / shares					$ 6
Number of vesting installments | Installments					2
Fair value of options granted | $					$ 41
Expiration date					Dec. 19, 2022
Expected dividend yield					0.00%
Expected volatility					64.35%
Risk-free interest rate					1.01%
Expected term					5 years 9 months
Unrecognized compensation expense | $						$ 14
Subsidiary Employee [Member]
Stock-Based Compensation (Textual)
Options granted				2,556
Options granted, exercise price | $ / shares				$ 12.45
Number of vesting installments | Installments				4
Fair value of options granted | $				$ 21
Expiration date				Apr. 9, 2024
Expected dividend yield				0.00%
Expected volatility				82.06%
Risk-free interest rate				1.65%
Expected term				5 years 2 months 16 days
Subsidiary Employee [Member] | Restricted stock units [Member]
Stock-Based Compensation (Textual)
Share-based Compensation awards granted	4,632
Number of installments | Installments	21
Quoted closing market share price | $ / shares	$ 6.39
Subsidiary Employee [Member] | Restricted stock units [Member] | One installment
Stock-Based Compensation (Textual)
Number of installments | Installments	1
Options vested in period	772
Subsidiary Employee [Member] | Restricted stock units [Member] | 20 equal monthly installments
Stock-Based Compensation (Textual)
Number of installments | Installments	20
Options vested in period	193
Subsidiary Employees Three [Member] | Restricted stock units [Member]
Stock-Based Compensation (Textual)
Share-based Compensation awards granted		63,216
Number of installments | Installments		23
Fair value of restricted stock units | $		$ 288
Quoted closing market share price | $ / shares		$ 4.56
Subsidiary Employees Three [Member] | Restricted stock units [Member] | One installment
Stock-Based Compensation (Textual)
Number of installments | Installments		1
Options vested in period		5,268
Subsidiary Employees Three [Member] | Restricted stock units [Member] | 22 equal monthly installments
Stock-Based Compensation (Textual)
Number of installments | Installments		22
Options vested in period		2,634
Board of Directors Four [Member]
Stock-Based Compensation (Textual)
Options granted				52,376
Options granted, exercise price | $ / shares				$ 12.45
Number of vesting installments | Installments				2
Fair value of options granted | $				$ 435
Expiration date				Apr. 9, 2024
Expected dividend yield				0.00%
Expected volatility				82.06%
Risk-free interest rate				1.65%
Expected term				5 years 2 months 16 days
Board of Directors Four [Member] | Restricted stock units [Member]
Stock-Based Compensation (Textual)
Number of shares reserved for grant		88,712	10,872
Number of installments | Installments		2
Options vested in period		44,356
Fair value of restricted stock units | $		$ 405	$ 75
Quoted closing market share price | $ / shares		$ 4.56	$ 6.90

Financial Income and Expenses55

Financial Income and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Financial income
Gain on sale of marketable securities (note 3b)		$ 80	$ 90
Changes in fair value of warrants			44
Income from interest on deposits	$ 160	$ 138	$ 19
Exchange rate differences		$ 7
Income from interest on corporate bonds	$ 8
Other			$ 27
Financial income	$ (168)	$ (225)	$ (180)

Financial Income and Expenses56

Financial Income and Expenses (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Financial expenses
Exchange of warrants			$ 297
Exchange rate differences	$ 3		3
Bank commissions	9	$ 11	$ 13
Other	6
Financial expenses	$ (18)	$ (11)	$ (313)

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Schedule of deferred income taxes
Net operating loss carryforward	$ 5,750	$ 4,890	$ 3,993
Research and development expenses	906	688	339
Less - valuation allowance	$ (6,656)	$ (5,578)	$ (4,332)
Net deferred tax assets

Taxes on Income (Details 1)

Taxes on Income (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Loss before taxes on income:
U.S.	$ 1,226	$ 893	$ 1,186
Outside U.S.	6,006	4,799	3,251
Total	$ 7,233	$ 5,692	4,437
Current:
Income tax expenses (benefit), U.S.			(13)
Income tax expenses (benefit), Outside U.S.	$ (1)	$ 4	(192)
Income tax expenses (benefit), Total	$ (1)	$ 4	$ (205)

Taxes on Income (Details 2)

Taxes on Income (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Schedule of reconciliation of income taxes
Loss before income taxes as reported in the consolidated statement of comprehensive income (loss)	$ 7,233	$ 5,692	$ 4,437
Statutory tax benefit	(2,531)	(1,992)	(1,552)
Increase (decrease) in income taxes resulting from:
Change in the balance of the valuation allowance for deferred tax	1,599	1,104	902
Disallowable deductions	422	480	374
Influence of different tax rates applicable to the Subsidiary	510	408	276
Uncertain tax position	(1)	4	(205)
Taxes on income for the reported year	$ (1)	$ 4	$ (205)

Taxes on Income (Details 3)

Taxes on Income (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
Schedule of unrecognized tax benefits activity
Balance at Beginning of Year	$ 27	$ 23	$ 228
Increase (decrease) in uncertain tax positions for the current year	(1)	4	(205)
Balance at End of Year	$ 26	$ 27	$ 23

Taxes on Income (Details 4)

Taxes on Income (Details 4) $ in Thousands	12 Months Ended
	Aug. 31, 2015USD ($)
Allowance in respect of carryforward tax losses:
Balance at beginning of period	$ 5,578
Balance at end of period	6,656
Year ended August 31, 2013 [Member]
Allowance in respect of carryforward tax losses:
Balance at beginning of period	3,208
Additions	1,124
Balance at end of period	4,332
Year ended August 31, 2014 [Member]
Allowance in respect of carryforward tax losses:
Balance at beginning of period	4,332
Additions	1,246
Balance at end of period	5,578
Year ended August 31, 2015 [Member]
Allowance in respect of carryforward tax losses:
Balance at beginning of period	5,578
Additions	1,078
Balance at end of period	$ 6,656

Taxes on Income (Details Textua

Taxes on Income (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
Corporate taxation in the U.S. [Member]
Taxes on income (Textual)
Corporate tax rate	35.00%
Accumulated tax loss carryforward	$ 7,569	$ 6,791
Carryforward tax losses expire	20 years
Net loss carryforward will expire years, Description	2025 through 2032.
Corporate taxation in Israel [Member]
Taxes on income (Textual)
Corporate tax rate	26.50%	26.50%
Accumulated tax loss carryforward	$ 11,701	$ 9,487

Related Parties - Transaction63

Related Parties - Transactions (Details) - USD ($) $ in Thousands	Aug. 31, 2015	Aug. 31, 2014
Related Party Transaction [Line Items]
Receivable		$ 330
Accounts payable and accrued expenses - KNRY	$ 36	47
KNRY [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses - KNRY	$ 36	$ 47

Related Parties - Transaction64

Related Parties - Transactions (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013
KNRY [Member]
Related Party Transaction [Line Items]
Expenses to related parties	$ 586	$ 671	$ 448

Related Parties - Transaction65

Related Parties - Transactions (Details Textual) - USD ($) $ in Thousands	Jul. 01, 2008	Mar. 18, 2014	Feb. 24, 2014	Aug. 31, 2015	Aug. 31, 2014	Aug. 31, 2013	Jul. 17, 2013
Related Parties Transactions (Textual)
Directors fees				$ 47	$ 40	$ 39
KNRY [Member]
Related Parties Transactions (Textual)
Consulting agreements, Description	The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid a gross amount of NIS 50,400 per month for each of the CEO and CTO ($14) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.
CEO [Member]
Related Parties Transactions (Textual)
Annual payment under consulting agreements							$ 250
Cash bonus			$ 120
Temporary increase in compensation per month for a specific period		$ 7
CTO [Member]
Related Parties Transactions (Textual)
Annual payment under consulting agreements							$ 200
Cash bonus			$ 65

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member]	1 Months Ended
	Oct. 22, 2015USD ($)
Subsequent Event (Textual)
Payments made by HLST	$ 50,000
Debt instrument, Payment terms description	The revised schedule of payments under the license, $11,000 would be paid up front and $26,500 would be payable upon achievement of certain milestones and conditions.